These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11929393)

  • 1. Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease.
    Chen CL; Orr WC; Verlinden MH; Dettmer A; Brinkhoff H; Riff D; Schwartz S; Soloway RD; Krause R; Lanza F; Mack RJ
    Aliment Pharmacol Ther; 2002 Apr; 16(4):749-57. PubMed ID: 11929393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease.
    Netzer P; Schmitt B; Inauen W
    Aliment Pharmacol Ther; 2002 Aug; 16(8):1481-90. PubMed ID: 12182748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of motilin agonist ABT-229 on gastro-oesophageal reflux, oesophageal motility and lower oesophageal sphincter characteristics in GERD patients.
    Van Herwaarden MA; Samsom M; Van Nispen CH; Verlinden M; Smout AJ
    Aliment Pharmacol Ther; 2000 Apr; 14(4):453-62. PubMed ID: 10759625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial.
    Talley NJ; Verlinden M; Snape W; Beker JA; Ducrotte P; Dettmer A; Brinkhoff H; Eaker E; Ohning G; Miner PB; Mathias JR; Fumagalli I; Staessen D; Mack RJ
    Aliment Pharmacol Ther; 2000 Dec; 14(12):1653-61. PubMed ID: 11121915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial.
    Talley NJ; Verlinden M; Geenen DJ; Hogan RB; Riff D; McCallum RW; Mack RJ
    Gut; 2001 Sep; 49(3):395-401. PubMed ID: 11511562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial.
    Shaheen NJ; Denison H; Björck K; Karlsson M; Silberg DG
    Gut; 2013 Sep; 62(9):1248-55. PubMed ID: 22730470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cisapride on nocturnal transient lower oesophageal sphincter relaxations and nocturnal gastro-oesophageal reflux in patients with oesophagitis: a double-blind, placebo-controlled study.
    Pehlivanov N; Sarosiek I; Whitman R; Olyaee M; McCallum R
    Aliment Pharmacol Ther; 2002 Apr; 16(4):743-7. PubMed ID: 11929392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease.
    Kahrilas PJ; Quigley EM; Castell DO; Spechler SJ
    Aliment Pharmacol Ther; 2000 Nov; 14(11):1503-9. PubMed ID: 11069322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress with novel pharmacological strategies for gastro-oesophageal reflux disease.
    Tonini M; De Giorgio R; De Ponti F
    Drugs; 2004; 64(4):347-61. PubMed ID: 14969571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease.
    Wilkinson J; Wade A; Thomas SJ; Jenner B; Hodgkinson V; Coyle C
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):86-93. PubMed ID: 30272584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
    Wada T; Sasaki M; Kataoka H; Tanida S; Itoh K; Ogasawara N; Oshima T; Togawa S; Kubota E; Yamada T; Mori Y; Fujita F; Ohara H; Nakao H; Sobue S; Joh T; Itoh M
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():2-9. PubMed ID: 15943840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease.
    Pace F; Negrini C; Wiklund I; Rossi C; Savarino V;
    Aliment Pharmacol Ther; 2005 Aug; 22(4):349-56. PubMed ID: 16098002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
    Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease.
    van Herwaarden MA; Samsom M; Rydholm H; Smout AJ
    Aliment Pharmacol Ther; 2002 Sep; 16(9):1655-62. PubMed ID: 12197845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
    Dickman R; Emmons S; Cui H; Sewell J; Hernández D; Esquivel RF; Fass R
    Aliment Pharmacol Ther; 2005 Sep; 22(6):547-55. PubMed ID: 16167971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors.
    Vakil NB; Huff FJ; Cundy KC
    Aliment Pharmacol Ther; 2013 Jul; 38(2):107-17. PubMed ID: 23721547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
    Thjodleifsson B; Rindi G; Fiocca R; Humphries TJ; Morocutti A; Miller N; Bardhan KD;
    Aliment Pharmacol Ther; 2003 Feb; 17(3):343-51. PubMed ID: 12562446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease.
    Simon B; Ravelli GP; Goffin H
    Aliment Pharmacol Ther; 1996 Jun; 10(3):441-6. PubMed ID: 8791975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of interstitial cells of Cajal on gastrointestinal motility induced by motilin receptor agonist ABT-229].
    Wang CH; Wang LC; Jiang X; Lan L; Liu L; Sun Y; Wang BX
    Zhonghua Er Ke Za Zhi; 2010 Apr; 48(4):254-9. PubMed ID: 20654011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.
    Thomas E; Wade A; Crawford G; Jenner B; Levinson N; Wilkinson J
    Aliment Pharmacol Ther; 2014 Mar; 39(6):595-602. PubMed ID: 24471505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.